Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etanercept in psoriasis.

Kim A Papp1

  • 1Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada. kapapp@probitymedical.com.

Expert Opinion on Pharmacotherapy
|October 6, 2004
PubMed
Summary
This summary is machine-generated.

Etanercept effectively treats moderate-to-severe psoriasis by targeting tumor necrosis factor (TNF). Clinical trials show sustained efficacy and good tolerability, with adverse events comparable to placebo.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

American journal of clinical dermatology·2026
Same author

Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study.

Expert opinion on investigational drugs·2026
Same author

Clinical proof of concept for small molecule mediated inhibition of IL-17 in psoriasis.

PloS one·2026
Same author

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis is a chronic skin condition affecting 2% of US and European populations.
  • Elevated tumor necrosis factor (TNF) levels correlate with psoriasis development.
  • Targeting TNF's inflammatory effects may resolve psoriatic lesions.

Purpose of the Study:

  • To evaluate the efficacy and safety of etanercept in treating moderate-to-severe psoriasis.

Main Methods:

  • Analysis of several well-controlled clinical trials involving etanercept for psoriasis treatment.

Main Results:

  • Etanercept demonstrated sustained efficacy in reducing psoriasis signs and symptoms.
  • Adverse event rates were similar to placebo, excluding injection site reactions.

Related Experiment Videos

  • No increase in adverse events was observed with higher etanercept doses.
  • No opportunistic infections, including tuberculosis, were reported.

    • Conclusions:

    • Etanercept is an effective and well-tolerated treatment option for moderate-to-severe psoriasis.
    • The biological agent shows a favorable safety profile in clinical trials.